and survival rates were improved in a small group of dogs with IMHA (although these patients also received other immunosuppressants) when compared with historical controls. The authors suggest that LC may have a role in treating antibodymediated cytopenias where macrophages play an important role by rapidly stopping erythrocyte or platelet destruction while gaining time for slower acting immunosuppressants to become effective. Based on these findings, prospective randomised pla-
cebo-controlled trials of LC are in progress at Colorado State University for management of IMHA in dog. CSU is also evaluating LC for efficacy in the management of malignant histiocytosis in dogs.